Mesirow Financial Investment Management Inc. Has $377,000 Stock Position in SPDR S&P Biotech ETF $XBI

Mesirow Financial Investment Management Inc. lowered its stake in SPDR S&P Biotech ETF (NYSEARCA:XBI) by 47.3% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 4,541 shares of the exchange traded fund’s stock after selling 4,071 shares during the quarter. Mesirow Financial Investment Management Inc.’s holdings in SPDR S&P Biotech ETF were worth $377,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the stock. Investment Partners Asset Management Inc. increased its position in shares of SPDR S&P Biotech ETF by 4.0% during the 2nd quarter. Investment Partners Asset Management Inc. now owns 3,257 shares of the exchange traded fund’s stock worth $270,000 after purchasing an additional 125 shares during the last quarter. Compass Ion Advisors LLC increased its holdings in SPDR S&P Biotech ETF by 3.9% during the second quarter. Compass Ion Advisors LLC now owns 3,727 shares of the exchange traded fund’s stock worth $309,000 after buying an additional 140 shares during the last quarter. McAdam LLC increased its holdings in SPDR S&P Biotech ETF by 5.1% during the second quarter. McAdam LLC now owns 3,273 shares of the exchange traded fund’s stock worth $271,000 after buying an additional 159 shares during the last quarter. First Heartland Consultants Inc. increased its holdings in SPDR S&P Biotech ETF by 2.7% during the first quarter. First Heartland Consultants Inc. now owns 6,344 shares of the exchange traded fund’s stock worth $514,000 after buying an additional 168 shares during the last quarter. Finally, Calton & Associates Inc. increased its holdings in SPDR S&P Biotech ETF by 3.2% during the first quarter. Calton & Associates Inc. now owns 5,662 shares of the exchange traded fund’s stock worth $459,000 after buying an additional 175 shares during the last quarter.

SPDR S&P Biotech ETF Price Performance

SPDR S&P Biotech ETF stock opened at $112.71 on Friday. The firm has a market capitalization of $6.87 billion, a PE ratio of 11.47 and a beta of 0.93. The company’s 50-day moving average is $100.28 and its 200-day moving average is $89.26. SPDR S&P Biotech ETF has a fifty-two week low of $66.66 and a fifty-two week high of $113.21.

SPDR S&P Biotech ETF Company Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.